Open AccessSlope of change in HbA 1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes
Author(s) -
DeFronzo Ralph A.,
Ferrannini Ele,
Schernthaner Guntram,
Hantel Stefan,
Elsasser Ulrich,
Lee Christopher,
Hach Thomas,
Lund Søren S.
Publication year - 2018
Publication title -
endocrinology, diabetes and metabolism
Language(s) - English
Resource type - Journals
ISSN - 2398-9238
DOI - 10.1002/edm2.16
Subject(s) - empagliflozin , glimepiride , sitagliptin , metformin , type 2 diabetes , medicine , diabetes mellitus , urology , endocrinology
Summary Aims To analyse the effect of baseline glycated haemoglobin (HbA 1c ) on the reduction in HbA 1c with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes. Materials and methods Using regression analyses of individual patient data from two Phase III studies, we compared the change in HbA 1c according to a unit change in baseline HbA 1c (the slope) with empagliflozin 10 mg or 25 mg vs sitagliptin (monotherapy) after 24 weeks, and with empagliflozin 25 mg vs glimepiride (as add‐on to metformin) after 52 weeks. Results Steeper slopes of HbA1c decline were observed with empagliflozin 10 or 25 mg vs sitagliptin monotherapy at week 24. Regression analysis showed slopes of −0.59 (95% CI −0.70, −0.47), −0.49 (95% CI −0.62, −0.37) and −0.29 (95% CI −0.42, −0.15) for empagliflozin 10 mg, empagliflozin 25 mg and sitagliptin, respectively ( P < .001 and P < .05 for empagliflozin 10 mg and empagliflozin 25 mg, respectively, vs sitagliptin). Similarly, a steeper slope of HbA 1c decline was observed with empagliflozin 25 mg vs glimepiride as add‐on to metformin at week 52. Regression analysis showed slopes of − 0.52 (95% CI −0.59, −0.44) and −0.32 (95% CI −0.39, −0.25) for empagliflozin 25 mg and glimepiride, respectively ( P < .001 for empagliflozin 25 mg vs glimepiride). Conclusions Incremental reductions in HbA 1c with increasing baseline HbA 1c are greater with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.